Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 6/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14078347 | 0.87 | TRPM8 (0.69) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14464537 | 0.87 | TRPM8 (0.84) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14610517 | 0.86 | TRPM8 (0.68) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL27088400 | 0.86 | TRPM8 (0.73) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL27088399 | 0.86 | TRPM8 (0.73) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14610513 | 0.85 | TRPM8 (0.72) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14463823 | 0.85 | TRPM8 (0.75) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL6326223 | 0.85 | TRPM8 (0.56) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14610369 | 0.84 | TRPM8 (0.66) | TRPM8MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL14464079 | 0.84 | TRPM8 (1.00) | TRPM8MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302171-A | Lymphocyte populations and methods for producing the same | AVM生物技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220409630-A1 | BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSTION | Rafarm SA (GR) | 2022-12-29 | — | — | US | disclosed |
| WO-2022253260-A1 | DETECTION KIT FOR NEUTRALIZING ANTIBODY FOR NOVEL CORONAVIRUS AND MUTANT STRAIN THEREOF | 南京金斯瑞生物科技有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-4051234-A1 | BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION | RAFARM S.A. (GR) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021240712-A1 | CIRCULATION CIRCUIT AND AIR CONDITIONING SYSTEM PROVIDED THEREWITH | 三菱電機株式会社 | 2021-12-02 | — | — | WO | disclosed |
| CN-113350272-A | Betamethasone sodium phosphate injection and preparation method and application thereof | 北京鑫开元医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| WO-2021084522-A1 | BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION | RAFARM UK LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| US-6963015-B2 | Ethylene-hexafluoropropylene copolymer elastomer | DAIKIN INDUSTRIES, LTD (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050228017-A1 | Novel anticancer compounds | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE | 2005-10-13 | — | — | US | disclosed |
| US-6858763-B2 | Process for preparing elastomeric ethylene-hexafluoropropylene copolymer | DAIKIN INDUSTRIES, LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20040214973-A1 | Process for preparing elastomeric ethylene-hexafluoropropylene copolymer | DAIKIN INDUSTRIES, LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1442018-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040030049-A1 | Ethylene/hexafluoropropylene copolymer elastomer | DAIKIN INDUSTRIES, LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| WO-2003037865-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | TP53, ABCG2, MCL1 | TRPM8 2570/4885MEN1 1347/4885KMT2A 3367/4885 |
| US-20220409630-A1 | BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSTION | ADRB2, BAK1, MYOC | TRPM8 38/4885MEN1 3733/4885KMT2A 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.